Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma

doi:10.7518/hxkq.2020.04.017

Abstract

Abstract:

Oral squamous cell carcinoma (OSCC) is a common malignant tumor in the oral and maxillofacial region. At present, the treatment of OSCC is mainly based on surgical oriented comprehensive sequence therapy, especially the triple therapy of surgery, radiotherapy, and chemotherapy. However, the overall five-year survival rate is relatively low. Therefore, researching the pathogenesis and treatment methods of OSCC is important. The immune checkpoint of programmed death receptor-1 (PD-1) and programmed death receptor-1 ligand (PD-L1) have been the focus of research in recent years. Several studies have shown that the high expression of PD-1/PD-L1 in most OSCC microenvironments may contribute to the immune escape of tumors. In this study, the research status of immune checkpoint of PD-1/PD-L1 and its relevant inhibitors in OSCC were reviewed.

Key words: programmed death receptor-1, programmed death receptor-1 ligand, oral squamous cell carcinoma

CLC Number:

R739.8

Chen Zhihong, Wu Yadong. Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma[J]. West China Journal of Stomatology, 2020, 38(4): 449-453.

References 43

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA: Cancer J Clin, 2018,68(1):7-30. doi: 10.3322/caac.21442 URL
[2]	Zhang LW, Li J, Cong X, et al. Incidence and mortality trends in oral and oropharyngeal cancers in China, 2005-2013[J]. Cancer Epidemiol, 2018,57:120-126. doi: 10.1016/j.canep.2018.10.014 URL pmid: 30396144
[3]	Omura K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma[J]. Int J Clin Oncol, 2014,19(3):423-430. doi: 10.1007/s10147-014-0689-z URL
[4]	Lyford-Pike S, Peng SW, Young GD, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013,73(6):1733-1741. doi: 10.1158/0008-5472.CAN-12-2384 URL pmid: 23288508
[5]	Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment[J]. Int J Oncol, 2017,50(1):41-48. doi: 10.3892/ijo.2016.3785 URL pmid: 27922697
[6]	Groeger S, Howaldt HP, Raifer H, et al. Oral squamous carcinoma cells express B7-H1 and B7-DC receptors in vivo[J]. Pathol Oncol Res, 2017,23(1):99-110. doi: 10.1007/s12253-016-0100-7 URL pmid: 27498988
[7]	Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015,348(6230):56-61. doi: 10.1126/science.aaa8172 URL
[8]	Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992,11(11):3887-3895. URL pmid: 1396582
[9]	Hansen JD, Du Pasquier L, Lefranc MP, et al. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective[J]. Mol Immunol, 2009,46(3):457-472. URL pmid: 19081138
[10]	Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016,375(18):1767-1778. doi: 10.1056/NEJMra1514296 URL pmid: 27806234
[11]	Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001,2(3):261-268. doi: 10.1038/85330 URL pmid: 11224527
[12]	Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis[J]. World J Clin Oncol, 2017,8(1):37-53. doi: 10.5306/wjco.v8.i1.37 URL pmid: 28246584
[13]	Syn NL, Teng MWL, Mok TS, et al. De-novo and acquired resistance to immune checkpoint targeting[J]. Lancet Oncol, 2017,18(12):e731-e741. URL pmid: 29208439
[14]	Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017,8:561. URL pmid: 28878676
[15]	Ock CY, Kim S, Keam B, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J]. Oncotarget, 2016,7(13):15901-15914. URL pmid: 26893364
[16]	Xu SH, Tao Z, Hai B, et al. MiR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint[J]. Nat Commun, 2016,7:11406. doi: 10.1038/ncomms11406 URL pmid: 27147225
[17]	Dong HD, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002,8(8):793-800. doi: 10.1038/nm730 URL pmid: 12091876
[18]	Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999,5(12):1365-1369. doi: 10.1038/70932 URL pmid: 10581077
[19]	Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma[J]. Oral Oncol, 2006,42(3):268-274. doi: 10.1016/j.oraloncology.2005.07.013 URL pmid: 16271509
[20]	Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma[J]. Oncotarget, 2017,8(68):112584-112597. URL pmid: 29348848
[21]	Maruse Y, Kawano S, Jinno T, et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma[J]. Int J Oral Maxillofac Surg, 2018,47(7):836-845. doi: 10.1016/j.ijom.2018.01.004 URL pmid: 29395669
[22]	Naruse T, Yanamoto S, Okuyama K, et al. Immunohistochemical study of PD-1/PD-L1 Axis expression in oral tongue squamous cell carcinomas: effect of neoadjuvant chemotherapy on local recurrence[J]. Pathol Oncol Res, 2020,26(2):735-742. doi: 10.1007/s12253-019-00606-3 URL pmid: 30767115
[23]	Cho YA, Yoon HJ, Lee JI, et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma[J]. Oral Oncol, 2011,47(12):1148-1153. doi: 10.1016/j.oraloncology.2011.08.007 URL pmid: 21911310
[24]	Troiano G, Caponio VCA, Zhurakivska K, et al. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: a Meta-analysis of the literature[J]. Cell Prolif, 2019,52(2):e12537. doi: 10.1111/cpr.12537 URL pmid: 30443950
[25]	de Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, et al. PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2019,28(3):546-554. doi: 10.1158/1055-9965.EPI-18-0779 URL pmid: 30487133
[26]	Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells[J]. Oncotarget, 2015,6(25):20902-20920. doi: 10.18632/oncotarget.3939 URL pmid: 26041877
[27]	张鹏, 欧阳少波, 王军, 等. 程序性死亡分子1及其配体在口腔鳞状细胞癌患者外周血中的表达及临床意义[J]. 华西口腔医学杂志, 2015,33(5):529-533.
	Zhang P, Ouyang SB, Wang J , et al. Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications[J]. West China J Stomatol, 2015,33(5):529-533.
[28]	王晓宁, 秦星, 王旭, 等. PD-L1下调对口腔鳞癌细胞生物学行为的影响[J]. 北京口腔医学, 2018,26(03):127-131.
	Wang XN, Qin X, Wang X , et al. Effect of PD-L1 downregulation on biological properties in oral squamous cell carcinoma[J]. Beijing J Stomatol, 2018,26(3):127-131.
[29]	Jiang CH, Yuan FL, Wang J, et al. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages[J]. Immunobiology, 2017,222(4):651-657. doi: 10.1016/j.imbio.2016.12.002 URL pmid: 28017495
[30]	邹波, 许凯, 刘宪斌, 等. PD-L1的表达与口腔鳞癌预后及临床病理特征相关性的meta分析[J]. 上海口腔医学, 2018,27(1):100-105.
	Zou B, Xu K, Liu XB , et al. Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis[J]. Shanghai J Stomatol, 2018,27(1):100-105.
[31]	Lomax AJ, Lim J, Cheng R, et al. Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management[J]. J Skin Cancer, 2018,2018:9602540. doi: 10.1155/2018/9602540 URL pmid: 29610684
[32]	Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3 URL pmid: 27247226
[33]	Patnaik A, Kang SP, Rasco D, et al. PhaseⅠstudy of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J]. Clin Cancer Res, 2015,21(19):4286-4293. doi: 10.1158/1078-0432.CCR-14-2607 URL pmid: 25977344
[34]	Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase ib KEYNOTE-012 expansion cohort[J]. J Clin Oncol, 2016,34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478 URL pmid: 27646946
[35]	Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study[J]. J Clin Oncol, 2017,35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524 URL pmid: 28328302
[36]	Cohen EE, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8 URL pmid: 30509740
[37]	Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol, 2014,32(10):1020-1030. doi: 10.1200/JCO.2013.53.0105 URL pmid: 24590637
[38]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867. doi: 10.1056/NEJMoa1602252 URL pmid: 27718784
[39]	Kiyota N, Hasegawa Y, Takahashi S, et al. A randomized, open-label, phase Ⅲ clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141[J]. Oral Oncol, 2017,73:138-146. doi: 10.1016/j.oraloncology.2017.07.023 URL pmid: 28939066
[40]	Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018,36(8):773-779. doi: 10.1200/JCO.2017.76.9901 URL pmid: 29355075
[41]	Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study[J]. JAMA Oncol, 2017,3(9):e172411. doi: 10.1001/jamaoncol.2017.2411 URL pmid: 28817753
[42]	周毅, 孙建国. 肿瘤免疫治疗引起免疫相关不良反应的若干思考[J]. 医药导报, 2019,38(8):1003-1007.
	Zhou Y, Sun JG . Commentary on immune-related adverse events of tumor immunotherapy[J]. Herald Med, 2019,38(8):1003-1007.
[43]	Lamichhane P, Deshmukh R, Brown JA, et al. Novel delivery systems for checkpoint inhibitors[J]. Medicines (Basel), 2019,6(3):E74.